INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial

Show full item record

Bookmark or cite this item: http://hdl.handle.net/10027/8534

Files in this item

File Description Format
PDF high frequency.pdf (308KB) (no description provided) PDF
Title: High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial
Author(s): Mahajan, Amit K.; Diette, Gregory B.; Hatipoğlu, Umur; Bilderback, Andrew; Ridge, Alana; Harris, Vanessa Walker; Dalapathi, Vijay; Badlani, Sameer; Lewis, Stephanie; Charbeneau, Jeff T.; Naureckas, Edward T.; Krishnan, Jerry A.
Subject(s): asthma chronic obstructive pulmonary disease high frequency chest wall oscillation airway mucus clearance
Abstract: Background: High frequency chest wall oscillation (HFCWO) is used for airway mucus clearance. The objective of this study was to evaluate the use of HFCWO early in the treatment of adults hospitalized for acute asthma or chronic obstructive pulmonary disease (COPD). Methods: Randomized, multi-center, double-masked phase II clinical trial of active or sham treatment initiated within 24 hours of hospital admission for acute asthma or COPD at four academic medical centers. Patients received active or sham treatment for 15 minutes three times a day for four treatments. Medical management was standardized across groups. The primary outcomes were patient adherence to therapy after four treatments (minutes used/60 minutes prescribed) and satisfaction. Secondary outcomes included change in Borg dyspnea score (≥ 1 unit indicates a clinically significant change), spontaneously expectorated sputum volume, and forced expired volume in 1 second. Results: Fifty-two participants were randomized to active (n = 25) or sham (n = 27) treatment. Patient adherence was similarly high in both groups (91% vs. 93%; p = 0.70). Patient satisfaction was also similarly high in both groups. After four treatments, a higher proportion of patients in the active treatment group had a clinically significant improvement in dyspnea (70.8% vs. 42.3%, p = 0.04). There were no significant differences in other secondary outcomes. Conclusions: HFCWO is well tolerated in adults hospitalized for acute asthma or COPD and significantly improves dyspnea. The high levels of patient satisfaction in both treatment groups justify the need for sham controls when evaluating the use of HFCWO on patient-reported outcomes. Additional studies are needed to more fully evaluate the role of HFCWO in improving in-hospital and post-discharge outcomes in this population.
Issue Date: 2011-09-10
Publisher: BioMed Central
Citation Info: Mahajan, A. K., Diette, G. B., Hatipoglu, U., Bilderback, A., Ridge, A., Harris, V. W., Dalapathi, V., Badlani, S., Lewis, S., Charbeneau, J. T., Naureckas, E. T., & Krishnan, J. A. 2011. High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial. Respiratory Research, 12: 120. DOI: 10.1186/1465-9921-12-120
Type: Article
Description: © 2011 Mahajan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. DOI: 10.1186/1465-9921-12-120
URI: http://hdl.handle.net/10027/8534
ISSN: 1465-9921
Date Available in INDIGO: 2012-08-17
 

This item appears in the following Collection(s)

Show full item record

Statistics

Country Code Views
United States of America 171
China 43
United Kingdom 9
Netherlands 6
Germany 3

Browse

My Account

Information

Access Key